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CASE PRESENTATION
A 7-year-old Mexican girl with a 2-year history of in-
termittent periorbital edema was seen several times by
her local physician in Tennessee for this complaint but
never received a diagnosis. While visiting Mexico with
her parents, she was diagnosed with the nephrotic syn-
drome. Urinalysis at presentation revealed 2+ protein
and 3+ blood, with 4 to 16 white blood cells and 8 to 10
red blood cells/high-power field but no casts in the uri-
nary sediment. Total protein was 4.6 g/dL; albumin, 1.6 g/
dL; cholesterol, 471 mg/dL; blood urea nitrogen (BUN),
25 mg/dL; and serum creatinine, 0.5 mg/dL. She was given
prednisone, 40 mg daily (50 mg/m2/day); after 1 month
the dose was tapered to 20 mg daily. She also received
methotrexate, 25 mg three times per week; spironolac-
tone, 12.5 mg daily; simvastatin, 20 mg daily; and a
multivitamin.
The child’s past medical history was essentially unre-
markable, with no prior illnesses or hospitalizations. A
review of systems was positive only for muscle cramps in
her legs. The girl’s 40-year-old mother has lupus nephritis
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and is being treated with steroids and azathioprine. The
maternal grandmother has a history of hypertension.
Six weeks after the patient’s diagnosis, she returned to
the United States and was evaluated at the University
of Tennessee pediatric nephrology clinic. Her weight was
20.9 kg (25th percentile for age) and height was 110.3 cm
(less than 5th percentile). The blood pressure was 111/85
mm Hg. Physical examination was notable for cushingoid
facies and the absence of periorbital or lower extremity
edema, or ascites. Urinalysis showed 2+ protein and 1+
blood, with 3 to 5 red blood cells/high-power field and a
single granular cast in the urinary sediment. The mother
was instructed to discontinue all the child’s medications
except steroids; the prednisone dose was increased to
55 mg daily in two divided doses (69 mg/m2/day), and
quinapril, 5 mg daily, was begun. The child was seen
2 weeks later; urinalysis showed 3+ protein and 2+ blood.
The urinary sediment contained 10 to 20 white blood cells
and 20 to 40 red blood cells/high-power field and hya-
line and granular casts. A chemistry panel revealed total
protein and albumin of 7.7 and 2.1 g/dL, respectively;
cholesterol, 297 mg/dL; BUN, 15 mg/dL; and serum crea-
tinine, 0.4 mg/dL. The C3 and C4 complement levels were
normal at 231 and 25.4 mg/dL, respectively. Antinuclear
antibody titer was negative. Hepatitis B surface antigen
and hepatitis C antibody were negative.
A renal biopsy done 9 weeks after diagnosis of the
nephrotic syndrome revealed focal segmental glomeru-
losclerosis (FSGS) with lesions in approximately 10% of
glomeruli. The quinapril was continued, and the patient
was begun on a regimen of high-dose pulse intravenous
methylprednisolone. She received the drug on alternate
days for 2 weeks, weekly for 9 weeks, every 2 weeks for
9 weeks, monthly for 8 months, and every other month for
6 months. At present, she is starting weekly intravenous
methylprednisolone therapy and is clinically stable.
DISCUSSION
DR. RUSSELL CHESNEY (Professor and Chair, Depart-
ment of Pediatrics, LeBonheur Children’s Medical Center,
Memphis, Tennessee, USA): Less than a century ago, sev-
eral German physicians separately described a condition
characterized by edema, proteinuria, hypoalbuminemia,
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and elevated plasma cholesterol values [1–4]. In effect,
they defined a distinct clinicopathologic entity that we
recognize as childhood nephrotic syndrome. This condi-
tion, in their judgment, could be distinguished from the
forms of chronic kidney disease described by Bright [5].
Of note, these German scholars had ample autopsy ma-
terial from children who died from inanition, malnutri-
tion, infection (especially peritonitis), and renal failure
[1–4]. Histologic material demonstrated lipid-containing
bodies within distal tubule cells; hence, these German
scientists termed this condition “lower nephron nephro-
sis” [3, 4]. Between the 1920s and 1950s, the discovery
of antibiotics and of oral glucocorticoids dramatically re-
duced the number of deaths from this disorder [6, 7]. Fur-
ther, from the 1950s onward, percutaneous renal biopsy
was selectively applied to patients with renal disease,
including nephrotic children, and the various histopatho-
logic forms of childhood nephrotic syndrome were char-
acterized [8]. With the establishment and organization of
the International Study of Kidney Diseases in Children
(ISKDC), large numbers of children were evaluated [9].
Because of a series of important prospective studies, the
pathology committee of the ISKDC, led by R. Habib, R.
White, and J. Bernstein, was able to describe the patho-
logic lesions found in children with nephrotic syndrome
[9, 10]. The most common form of nephrotic syndrome
in children between age 1 year and adulthood [childhood
nephrotic syndrome, CNS)] was minimal lesion nephrotic
syndrome (MLNS) or nil disease. This was followed
by idiopathic FSGS, mesangial proliferative (MP), and
mesangioproliferative glomerulonephritis (MPGN), and
membranous nephropathy (MN) [7–9]. These studies and
others revealed that MLNS accounted for 60% to 85% of
biopsy-proven CNS [7, 9–11]. As became widely recog-
nized, most of these patients responded to 4 to 6 weeks of
oral prednisone therapy (up to 98% in some studies), and
most steroid-responsive nephrotic children had MLNS.
This duality of truths—that most children with nephrotic
syndrome had MLNS and that most steroid-responsive
cases of CNS had MLNS—has led pediatric nephrologists
initially to treat nephrotic children with glucocorticoids
for 4 to 12 weeks and to recommend a renal biopsy mainly
in those who fail to respond to glucocorticoid therapy.
This situation held until the early 1990s when it became
apparent that the prevalence of each of the major forms
of the nephrotic syndrome was changing [12, 13]. Simi-
lar observations were being made in adult series [14, 15].
This Forum will examine these apparent changes and the
evidence for this observation.
Epidemiology
Several recent reports suggest that the relative fre-
quency of FSGS is increasing as that of MLNS declines
[12–17]. This appears to be a phenomenon in African
American children in the northeastern United States [12],
in the South [13], and in the Midwest [16]. The finding
that FSGS is increasing is also found in India [17, 18],
Saudi Arabia [19], Iran [20], and South America [21].
These observations have necessitated re-examination of
the indications for biopsy in CNS [22]. Pediatric nephrol-
ogists now frequently recommend that children with the
typical clinical features of FSGS (hypertension, hema-
turia, heavy proteinuria, and renal insufficiency) undergo
biopsy at presentation. Of note, the frequency of MN and
MPGN are essentially unchanged from the low percent-
ages noted in the 1960s and 1970s [7–9]. The magnitude
of change is characterized by a tripling (or higher) of the
overall rate of FSGS in a series of biopsies performed in
children. The percentage of biopsies with FSGS was in
the range of 7% to 10% in the 1960s and 1970s [7, 9, 10].
Recent series, however, show 20% to 60% of biopsies
demonstrating this lesion [14–16] with, notably, a higher
frequency of FSGS in African American versus white pa-
tients, whether children [14–15] or adults [23].
Studies regarding the increased incidence of FSGS
in children should be interpreted with caution, as clin-
ical practice is changing with respect to which patients
with nephrotic syndrome should undergo renal biopsy.
In years past, it has been the custom to biopsy steroid-
dependent or frequently relapsing nephrotic patients be-
fore starting an alkylating agent. However, recent studies
have shown that steroid responsiveness confers a good
prognosis regardless of morphologic findings, and many
nephrologists now confine renal biopsy to patients with
glucocorticoid nonresponsiveness [22, 24, 25]. The sec-
ond problem is the issue of race [25], which has been
made more complex with findings by the human genome
project that a remarkable similarity of DNA exists among
all races as well as in the known mixtures of races, par-
ticularly African American and Hispanic populations in
North America. The problem of selection of which pa-
tients should undergo renal biopsy is of greater concern in
children, as most adults do undergo a renal biopsy. How-
ever, even with more strict selection criteria, a prevalence
of FSGS of 60% to 70% is consistent with a marked in-
crease in the frequency of this form of disease. Cameron
[25] reviewed the percentage of all nephrotic patients
seen at Guy’s Hospital in London in the 1960s and 1970s.
Seven percent of the children under age 15 had FSGS, and
19% of individuals between the ages of 15 and 19 years
had this diagnosis. In adult patients, FSGS ranged from
11% to 28%. When comparable, more recent data were
reviewed at Guy’s Hospital, the percentage of children
with FSGS was 23% in white and 57% in black patients
[23]. Again, as mentioned, these simple racial designa-
tions may be problematic [23].
Two recent reports examined predominantly white
children. In a series from a large Spanish glomerular
disease registry, the frequency of FSGS among different
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forms of biopsy-proven nephropathy in children during
1994 to 1999 was 15.2% [26]. This series captured all the
biopsy reports in the country of Spain from children un-
der age 15 and demonstrated a twofold increase in the
current percentage of FSGS when compared to the in-
formation available from the 1970s. A Canadian study
utilizing data from a 17-year-old database of 225,000 chil-
dren in eastern Ontario with mandatory referral [27]
estimated the incidence of nephrotic syndrome and its
subtypes. The incidence of FSGS rose significantly from
0.37 to 0.94/100,000 children/year in the two 8.5-year in-
tervals of this study. This study thus definitively points
out an increasing incidence of FSGS in children with id-
iopathic nephrotic syndrome over the last 2 decades.
Pathophysiology
In most series that describe an increasing frequency
of FSGS, the authors stipulate that they refer to pri-
mary FSGS [28], not the large number of “secondary
causes” of FSGS [23, 28]. Some of the “secondary causes,”
including AIDS nephropathy, were not relevant in series
in the 1960s and 1970s [7–9]. Further, the fact that the
fundamental pathology of primary FSGS has essentially
remained the same as in earlier reports, at least for the
classic lesion [29, 30], makes the point that MLNS and
FSGS “are often studied together for the traditional rea-
son that they seemed to be the findings in lipoid nephrosis
in the days when that diagnosis was used and considered
a single type of disease.” Nevertheless, the pathologic
features of FSGS cover a wide group of vasculitic, dia-
betic, and postinfections causes [31]. Primary (idiopathic)
FSGS refers to the classic lesion, collapsing glomerulopa-
thy, the cellular variant, and the glomerular tip lesion [23,
24, 32]. In the classic lesion, involved glomerular capil-
laries are affected by a collagenized scar and wrinkled
basement membranes [31]. A fibrous scar might exist be-
tween the involved segment and Bowman’s capsule. Un-
involved segments of focally obliterated glomeruli and
uninvolved glomeruli are normal. Trapping of IgM and
C3 is frequently found in segmental scars and areas of
hyalinosis. On the other hand, the collapsing lesion is typ-
ified by segmental or global collapse of capillaries, which
might contain foam cells associated with hypertrophy and
hyperplasia of the encompassing visceral epithelial cells
[33]. When a cellular lesion is isolated to the tip or take-
off of the proximal tubule, it is termed the glomerular tip
lesion [29]. Some people believe that the cellular variant
lesion is similar to the collapsing variant [31].
The pathophysiology of FSGS likely begins in the
glomerulus [34] and later extends into the tubulointer-
stitium at the urinary pole (tip lesion). Another major
feature of disease progression is podocyte loss, followed
by hypertrophy of remaining podocytes, with further
podocyte loss and fixation of parietal cells to Bowman’s
capsule. With tuft lesions, perfused capillaries empty their
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Fig. 1. Pathways along which a tuft adhesion might progress to loss of
the entire nephron or to formation of a segmental adherent scar.
contents into the interstitium rather than into Bowman’s
space. The major question is whether progression of re-
nal insufficiency in FSGS relates to podocyte damage or
interstitial fibrosis. Kriz [35], using evidence from a rat
model, showed that the latter podocyte damage, followed
by misdirected filtration, leads to nephron damage with
progression of the segmental lesion, degeneration of the
corresponding tubule, and localized interstitial fibrosis
(Fig. 1). In this model, interstitial fibrosis only arises as a
consequence of progressive podocyte damage [34, 35].
Genetic forms of FSGS
Recently, several genetic variants of FSGS have fur-
ther demonstrated the importance of a healthy podocyte
in maintaining a normal filtration barrier. While famil-
ial FSGS is found in a number of conditions, including
Laurence-Moon-Biedl, Denys-Drash, and Frasier syn-
dromes [36], primary familial FSGS is a part of at
least three, and possibly four, gene loci. An autosomal-
recessive mutation in a gene at 1q25-31 is the gene for
steroid-resistant nephrotic syndrome 2 (MPHS2) and
code for podocin [37, 38]; another autosomal-recessive
mutation at 19q13 appears to be the gene for a-actinin-4
and NPHS1 [36, 39]. NPHS1, at locus 19q13.1, the site
for the podocyte-associated nephrin, usually results in
congenital nephrotic syndrome, but can occur in FSGS
[40]. The third locus, 11q21-22, in contrast to the other
two loci, is associated with autosomal-dominant disease
rather than autosomal-recessive disease [36]. The link-
age of these gene products to podocyte biology is that
podocin links ion channels to the cytoskeleton [37, 41],
nephrin homoduplexes form the slit diaphragm [35, 36,
42], and a-actinin-4 decides cytoskeleton deformability
[36, 37, 43].
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Using the criteria of three or more family members
being affected with nephrotic syndrome, a number of
genetic consortia have screened families to better under-
stand the frequency of familial FSGS and the pathophys-
iology of disease [39]. While these three loci account for
the gene deficits in many families, an undefined locus (or
loci) is relevant in other families [44, 45]. As Winn points
out, recurrence of FSGS following a renal transplant in
patients with familial FSGS is very uncommon [44]; this
finding probably indicates that the locus for proteinuria,
scarring, and progression of renal disease lies in the kid-
ney or glomerulus per se [44]. The discovery of these gene
markers has led to an intense search for familial forms of
FSGS. These familial forms might account for a substan-
tial number of children or adults with FSGS, as they are
more common than previously thought [45].
I will now discuss a series of careful studies of ge-
netic FSGS. Fuchshuber et al [46] studied nine multi-
plex families in Europe and northern Africa with an
autosomal-recessive mode of inheritance. In the affected
subjects, onset of steroid-resistant idiopathic nephrotic
syndrome occurred between three months and five years
of age. End-stage renal disease occurred before 10
years of age, but recurrent disease did not occur after
renal transplantation. Linkage analysis mapped the gene
to chromosome 1q25-31. This NPHS2 gene encodes the
podocyte membrane protein podocin, and many of the
mutations are the result of abbreviated protein [38].
Tsukaguchi et al [47] investigated six FSGS fami-
lies with an autosomal-recessive inheritance pattern and
showed linkage to 1q25-31 in five. In comparison to fam-
ilies in the Fuchshuber study, these families had an older
age of onset and a more variable course, with 70% of
the affected patients developing ESRD at a mean age of
26 years (range 14 to 36 years). FSGS also did not recur
after renal transplantation.
Others have studied familial FSGS with an autosomal-
dominant inheritance pattern. Mathis et al [48] reviewed
73 members of a 100-member family from Oklahoma.
Eleven developed ESRD in the fifth decade of life. Seven
had proteinuria >1 g/24 hours with normal renal function.
Histology included FSGS and diffuse glomerulosclerosis.
The gene locus was mapped to chromosome 19q13.
Of interest is that this chromosome region included the
NPHS1 gene for congenital nephrotic syndrome of the
Finnish type, which is inherited in an autosomal-recessive
manner [39].
Kaplan et al [49] narrowed the gene locus for
this Oklahoma family by including two other families
with autosomal-dominant FSGS: a large family from
the Canary Islands and a small family from Califor-
nia, with a 19q13.1 locus each. A less severe disease
course was shared among these families in general.
The nephrin-encoding NPHS1 gene was not the source
of disease in these families. This study found A682G,
C695T, and T703C mutations in the alpha-actinin-4
gene.
Vats et al [40] studied a Pittsburgh family of mixed
African American and white ethnicity and showed link-
age to the 19q13. An autosomal-dominant inheritance
pattern and significant proteinuria was apparent in this
three-generation family with 10 affected individuals. On
average, proteinuria was 2.32 g/day (range 0.87 to 7.76 g/
day). In contrast to other autosomal-dominant fami-
lies linked to the 19q13 locus, the affected among the
Pittsburgh family presented early, mean age of 18.4
months, with a range from three months to four years.
Histology in this family included minimal change disease,
mesangial proliferative GN, and FSGS.
Additionally, Winn et al [50] studied two autosomal-
dominant FSGS families with linkage to 11q21-22 in one
of the families, a 399-member white kindred of British
heritage from New Zealand. Fourteen family members
developed ESRD; three members had >3+ proteinuria;
10 of the 12 biopsied exhibited FSGS. Mean age of re-
nal disease at presentation was 33 years (range 16 to
61 years). Proteinuria at presentation was 3.3 g/day (range
0.3 to 6.5 g/day). The average onset of ESRD was 10 years
(range 4 to 20 years). The affected gene within 11q-21 is
currently unknown.
The second cohort was a white family from North
Carolina with five affected individuals. Two biopsies of
affected members were consistent with FSGS.
Clinical features
While proteinuria and the nephrotic syndrome are the
main features in children with FSGS, not all of these
children will develop the full-blown nephrotic syndrome
[29]. In general, 88% of children with FSGS are nephrotic
[29]. Of these, 54% are male, 26% are hypertensive,
50% present with hematuria, and 19% present with renal
insufficiency. In contrast to classic FSGS, more black pa-
tients are likely to have a cellular or collapsing lesion
and are more likely to have nephrotic syndrome than are
white patients [50]. These black patients appear to ad-
vance to renal insufficiency (sometimes termed the “ma-
lignant” form of the disease) more rapidly [51, 52]. An
azotemic presentation is also common [51, 52]. Children
with massive proteinuria appear to have a more malig-
nant course and usually progress to end-stage renal dis-
ease (ESRD) in less than a decade [12, 14, 15, 53].
Two series of children from West Africa with nephrotic
syndrome (N = 330 children) indicate a high frequency of
hypertension (23% and 41%), and hematuria (26% and
60%) [54, 55]. Nonresponsiveness to steroids and other
immunosuppression also was high, at 31.1% and 48.3%,
respectively. The mortality rate, mainly from renal fail-
ure, was 5.5% and 6.9%. In East Africa, 37 of 60 children
with idiopathic disease (62%) had a low selective pro-
tein index and more extensive proteinuria; many of these
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low-selectivity patients were hypertensive and not re-
sponsive to steroids [56]. Although these three studies
did not have renal biopsy information, they do suggest
more extensive disease (and possibly FSGS) in African
patients.
Therapy
At present there exist no consistently reliable thera-
pies for primary FSGS, a disorder that can lead to ESRD
in children [29, 53]. In view of the fact that we have
no specific therapy, the treatment options are frequently
governed by trials [29, 57, 58]. A large multicenter trial
is being sponsored by the NIH but is not yet enrolling
patients.
Currently, the initial therapy for childhood nephrotic
syndrome comprises oral glucocorticoids (prednisone
at 60 mg/m2/day in divided doses). Much information
is available concerning the treatment of children with
MLNS, and meta-analysis [57, 58] indicates that initial
prednisone therapy of 12 weeks’ duration produces sig-
nificantly fewer relapses at 12 to 24 months. Initial ther-
apy in FSGS also should be prednisone, as approximately
25% (range, 0% to 51%) of biopsy-proven FSGS re-
sponds, according to a review of 15 series [29]. By con-
trast, 75% are steroid nonresponders. Steroid-responsive
patients tend to be free of disease 15 years later. In con-
trast, 50% of nonresponders double their serum creati-
nine value within 4 years.
Most relapsing patients (80%) [59–61] undergo remis-
sion with prednisone therapy. In those who do not, a
course of cyclophosphamide (2 mg/kg/day) or chloram-
bucil (0.1 to 0.2 mg/kg/day) is given with steroids. In
steroid-responsive children (N = 25) 52% had a com-
plete remission, 20% a partial remission, and 28% had
no response [29]. With steroid-resistant patients (N =
140), 80% had only a partial or no remission [29]. Alter-
native strategies include cyclosporine (5 to 6 mg/kg/day),
which can induce remission. Response is rapid, usually in
the first month. Unfortunately, a relapse usually occurs
within 2 months of tapering of steroids. Of 151 steroid-
resistant children, 43% responded to cyclosporine ther-
apy with complete remission [62]. One study indicated
less responsiveness of steroid-nonresponsive nephrotic
syndrome, with only 19% of 226 patients achieving com-
plete remission and 18% partial remission [63]. In a study
evaluating renal biopsy prior to cyclosporine administra-
tion, glomerular or interstitial scarring presaged a partial
rather than a complete remission in 23 children from one
center [62]. Intravenous methylprednisolone, 30 mg/kg
in a precise dosage schedule, usually given with cytotoxic
agents [64], can offer benefit as well. Remission following
methylprednisolone has been as high as 66%, but sev-
eral series had much less success [65 abstract: Guillot AP
et al, J Am Soc Nephrol 4:276, 1993].
A mainstay of therapy in steroid-resistant FSGS is the
use of angiotensin-converting-enzyme (ACE) inhibitors,
which reduce proteinuria and the rate of decline in
glomerular filtration rate (GFR) in a variety of forms
of glomerular disease [66]. The value of angiotensin II
receptor blockers has been studied in only a few children
and is anecdotal at present [67].
Another therapeutic agent is mycophenolate mofetil,
which in sporadic reports and open-label trials re-
sulted in relapse in <50% of patients; controlled trials
are currently being conducted [68]. Nonsteroidal anti-
inflammatory agents also have been used, usually in asso-
ciation with ACE inhibitors. This therapeutic approach,
although it sometimes reduces proteinuria, has the disad-
vantage of causing a decline in GFR and a rise in serum
potassium values [29].
Patients with malignant FSGS or ESRD have the op-
tions of dialysis and transplantation. Therapy of recurrent
disease in a transplanted kidney consists of a variety of
approaches, including plasma exchange and cyclophos-
phamide, plasma protein absorption, ACE inhibitors,
cyclosporine, and tacrolimus. Newstead [69] offers one
therapeutic approach. The North American Pediatric
Renal Transplant Cooperative Survey (NAPRTCS) eval-
uated the outcome of renal transplantation in adolescents
with FSGS. Graft survival was worse (56% at 5 years) in
FSGS patients who received a living related donor trans-
plant than in patients without FSGS (77% at 5 years) [70].
The survey concluded that FSGS has a negative impact
on graft survival in adolescents.
CONCLUSIONS
The frequency of FSGS in children over the past two
decades has increased dramatically. The reason for this
increase is unclear, but some authorities attribute it to
a more precise recognition of renal histopathologic vari-
ants of FSGS [29, 71, 72]. We’ve also seen a marked rise
in the incidence of FSGS in African American children;
the prevalence of primary FSGS in this population has
increased approximately threefold [14, 29]. If a toxin or
environmental factor is responsible for a higher percent-
age of children with FSGS, this has not been identified.
Other contributing factors such as obesity and hyperten-
sion, both public health problems in the United States
[73], also have not been evaluated. Finally, the recent ob-
servations from Italy that more than 12% of children
with steroid-responsive and steroid-resistant nephrotic
syndrome show mutations in glomerular proteins indi-
cate that the etiology of CNS, most of whom had FSGS,
is far more complex [37] than previously appreciated.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts
University School of Medicine, Boston, Massachusetts,
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USA): What do you think accounts for the extraordinarily
large difference between the various pathologic types of
nephrotic syndrome seen in children and adults? For ex-
ample, approximately 2% of children with the nephrotic
syndrome develop MN, whereas this type occurs in 40%
to 50% of adults with NS. Why are children resistant to
MN? Or why are adults more prone to it?
DR. CHESNEY: In children, many cases of membranous
nephropathy are related to hepatitis B, but I don’t know
why there is a higher prevalence of hepatitis B in adults.
DR. ROBERT J. WYATT (Professor of Pediatrics, Uni-
versity of Tennessee College of Medicine, Memphis): Most
of the adults in the United States who demonstrate idio-
pathic MN do not have hepatitis B.
DR. CHESNEY: I agree. Perhaps adults are more prone
to autoimmune phenomena that result in the planted anti-
gens found in MN.
DR. SERGIO ACCHIARDO (Professor of Medicine,
Nephrology, University of Tennessee College of
Medicine): My question refers to the 25% of pa-
tients who respond to steroids. In adults, at least, the
Canadian studies produced different results than those
in the United States. What percentage of this 25% of
patients who respond is African American?
DR. CHESNEY: In general, the response in African
Americans has been much lower. Patients with an African
ancestry in other countries such as England have similar
poor outcomes.
DR. WYATT: We have little epidemiologic data for
FSGS. Most of the statements are about “incidence.” The
studies are not population-based. They offer inferences
from the percentage of patients with FSGS in series of pa-
tients biopsied for nephrotic syndrome or from the whole
cohort diagnosed with glomerular disease. How can we be
sure that incidents of FSGS have increased dramatically
over the last decade or two?
DR. CHESNEY: As I mentioned, the Spanish study that
examined all biopsies in Spain is particularly relevant
[26]. The recent Eastern Ontario study is also relevant
because the government of Ontario directs patients to
one center [27]. Both studies clearly indicate more FSGS
now than in the past.
DR. DEBBIE JONES (Associate Professor of Pediatrics–
Nephrology, University of Tennessee College of
Medicine): Given the recent favorable treatment
response to cyclosporine, what is the role of the
Mendoza protocol in steroid-resistant FSGS [64]?
DR. CHESNEY: Several centers outside Los Angeles
and Stanford/University of California at San Diego have
failed to observe the high rates of remission that Men-
doza et al [64] found. However, cyclosporine still might
be the best first-line therapy after the usual course of oral
prednisone. Alkylating agents were used in the major-
ity of patients treated in Mendoza’s study [64], but they
were not added as frequently in the small series reported
by Guillot and Kim [abstract; Guillot AP, Kim MS, J Am
Soc Nephrol 4:276, 1993] and by Waldo et al [65].
DR. BETTINA AULT (Associate Professor of Pediatrics–
Nephrology, University of Tennessee College of
Medicine): What role do you think changing prac-
tice patterns in pediatric nephrology, specifically, the
practice of not biopsying steroid-responsive nephrotics
before giving an alkylating agent, have had in increasing
the relative incidence of FSGS in biopsy series?
DR. CHESNEY: We don’t really know, but it clearly plays
a role. Moreover, this practice of not biopsying steroid-
responsive nephrotics before giving an alkylating agent
is a worldwide phenomenon [71].
DR. NOEL DELOS SANTOS (Instructor of Pediatrics,
Nephrology Research, University of Tennessee Health
Science Center): Investigations into the familial forms
of nephrotic syndrome produced a newer classification
according to the underlying defects in podocyte biol-
ogy, namely, mutations in nephrin in the autosomal-
recessive congenital nephrotic syndrome of the Finnish
type, podocin in autosomal-recessive FSGS, and alpha-
actinin-4 in autosomal-dominant FSGS. Have studies on
the genetic forms of FSGS found homogenous disease
among patients with defects in either podocin or alpha-
actinin-4?
DR. CHESNEY: Linkage anaylysis is providing impor-
tant insights about FSGS [74–76]. This information might
allow us to personalize therapy for nephrotic syndrome
and dictate who should receive therapy. A valuable ther-
apeutic implication is the discovery that those with the
autosomal-recessive NPHS2 podicin mutation are typi-
cally resistant to steroid therapy. In the future, patients
with this genetic background might be able to avoid cor-
ticosteroids and the attendant side effects.
DR. DELOS SANTOS: Is anyone investigating the
genetic background of patients with steroid-sensitive
nephrotic syndrome?
DR. CHESNEY: Mutations in the NPHS2 gene encod-
ing the podocin mutation in autosomal-recessive FSGS
also have been exhibited in sporadic FSGS. Karle et al
[74] studied 27 multiplex families and 25 individuals with
sporadic steroid-resistant idiopathic nephrotic syndrome.
They wrote, “The characteristic features defining the clin-
ical diagnosis of SRINS [sporadic steroid-resistant idio-
pathic nephrotic syndrome] included familial occurrence,
age at onset in early childhood, resistance to steroid ther-
apy, progression to end-stage renal disease within a few
years, and absence of recurrence after renal transplanta-
tion.” Twelve members of the family with SRINS and 7
of the 25 “sporadic” patients had defects in the NPHS2
gene. These patients presented with >40 mg/m2/hour pro-
teinuria (two had >1000 mg/m2/hour). Average age of
onset was 3 years (range, 0.1 to 16.6 years). Of the 31, 21
progressed to ESRD within 7.4 years on average (range,
1.6 to 19.5 years). The 16 patients who underwent renal
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transplantation experienced no recurrence. Twenty-one
patients had FSGS histology; six had minimal change dis-
ease. This study reported five novel NPHS2 mutations:
A284V, R196P, V290M, IVS4-1G→T, and 460-467insT.
As Pollak et al [75] stated, “The utility of NPHS2 testing
to determine response to treatment still needs to be veri-
fied. NPHS2 was cloned on the basis of a shared steroid-
resistant phenotype within families. While the nature of
the NPHS2-associated disease will be steroid-resistant,
this needs verification by testing steroid-sensitive popu-
lations of sporadic NS. If NS individuals with two mutant
NPHS2 alleles are, as a rule, steroid-resistant, then ge-
netic testing will be of great value in tailoring therapy.”
Fuchshuber et al [76] described a family with steroid-
responsive idiopathic nephrotic syndrome with exclusion
of linkage to the NPHS2 gene. An autosomal-recessive
inheritance pattern was seen in these 15 families with 32
affected. The families originated from Germany, Switzer-
land, Italy, and the Czech Republic. All initially pre-
sented with proteinuria >40/mg/m2/hour. Renal function
and blood pressure remained normal. Zero to three re-
lapses were reported in 20 of the 32. More than four re-
lapses occurred in 12. Three were considered frequent
relapsers and five as steroid-dependent. Cytotoxic ther-
apy was used in addition to corticosteroids in frequent
relapsing and steroid-dependent patients. Of the 32, 12
biopsies had minimal change histology. Median age at
onset was 3.4 years (range, 7 months to 14 years).
Ruf et al [77] went on to identify a gene locus for
steroid-sensitive nephrotic syndrome (SSNS1) to chro-
mosome 2p by total genome search for linkage in a con-
sanguineous SSNS kindred originating from Germany.
The parents of the three children are second-degree
cousins.
DR. HARRINGTON: I have two questions. First, in pa-
tients with familial defects in podocyte proteins as a cause
of their FSGS, do they make antibodies, say to nephrin
or a-actinin-4, after transplantation? This phenomenon
would be analogous to the production of anti-glomerular
basement membrane (GBM) antibodies in patients with
Alport’s syndrome who receive transplants.
DR. CHESNEY: Thus far, few familial cases have shown
recurrence, but we should probably anticipate such a
mechanism of recurrence.
DR. HARRINGTON: Second, can we learn how to treat
patients from studies in experimental FSGS?
DR. CHESNEY: The model Kriz [35] describes demon-
strates the importance of the podocyte lesion. Therapy,
perhaps ACE inhibitors, should be directed toward these
changes in the podocyte.
DR. HARRINGTON: How long does it take for the
podocyte defect in minimal change disease to reverse af-
ter treatment with steroids is initiated?
DR. CHESNEY: One would assume that it occurs
promptly, but one can never know because who would
ever biopsy a child just after he or she responded to treat-
ment?
DR. WESAM BALLOUK (Medical Resident, Graduate
Medical Education, University of Tennessee College of
Medicine): Why in the familial form doesn’t FSGS recur
after transplantation?
DR. CHESNEY: Probably because the genetic defect re-
sides in proteins that form the structure of the podocyte
and the slit diaphragm.
DR. SHANE ROY III (Professor of Pediatrics, Univer-
sity of Tennessee Health Science Center): Because of the
increased prevalence of FSGS, should we be doing uri-
nalyses in school-age children in high prevalence areas?
DR. CHESNEY: In general, the cost-effectiveness of
population screening is not valuable. Furthermore, most
children with idiopathic primary FSGS (90%) will
present with the nephrotic syndrome [29].
DR. ROY: Should we treat children with asymptomatic
FSGS aggressively? For example, what about children
who are not nephrotic?
DR. CHESNEY: We have no data concerning this issue.
ACE inhibitors have been used in this situation.
DR. KEITH LAU (Pediatric Nephrology Fellow, Univer-
sity of Tennessee Health Science Center): Are we able to
predict who is going to relapse after transplantation?
DR. CHESNEY: No. Recurrence rates as high as 30%
to 50% have been described [28, 54, 70, 78, 79]. In-
vestigators have been looking for the existence of cir-
culating permeability factor(s) that might be the cause
of FSGS recurrence [80, 81]. A recent study from Vir-
ginia Savin’s group showed that patients who experi-
ence post-transplant recurrence exhibit higher perme-
ability activity in their plasma [82]. This, however, is still
a nonspecific finding. There exist patients with low per-
meability activity who have FSGS recurrence as well as
high-permeability patients who do not. Recurrence of
FSGS after transplantation in patients with podocin mu-
tations and non-genetic disease (sporadic) also can occur
[83].
DR. GABER: A high rate of recurrence of nephrotic
syndrome in children receiving a renal allograft from
an identical twin was reported in the early era of trans-
plantation. How do these data compare to what we cur-
rently know about post-transplantation outcome in fa-
milial nephrotic syndrome?
DR. CHESNEY: Most patients with familial FSGS do
not have recurrence after receiving a transplant, but pa-
tients with sporadic FSGS and podocin mutations can
have a recurrence [83]. If one believes in a “double-hit”
hypothesis, some other factor might be responsible for
recurrence in these patients with sporadic FSGS [44, 46].
DR. AULT: What is your opinion of the importance
of the various classifications of the FSGS lesion (the
glomerular tip lesion, the “classical” FSGS lesion, the
cellular FSGS variant, etc.)?
Nephrology Forum: Childhood nephrotic syndrome 1301
DR. CHESNEY: I think that the recent study of HIV
nephropathy by Winston et al [84] showing that the so-
called “collapsing” FSGS lesion of HIV nephropathy was
reversible in a patient treated with highly active anti-
retroviral therapy argues for the fact that the appear-
ance of the glomerulus in the “cellular” and “collapsing”
FSGS variants might be related to reversible podocyte
hypertrophy.
DR. AULT: What is your opinion of the significance of
the various “FSGS factors?”
DR. CHESNEY: Nephrologists have for years postu-
lated an “FSGS factor,” starting with Shalhoub in 1974
[85]. This speculation was sparked by the observation
of recurrent proteinuria after transplantation in patients
whose primary renal disease was FSGS. Zimmerman [81]
demonstrated in 1984 that plasma from some FSGS pa-
tients produced proteinuria in rats when injected into
the aorta. Savin et al [80] developed an assay of al-
bumin permeability in isolated glomeruli and showed
a higher value in patients with recurrent FSGS. Subse-
quent attempts at characterizing this permeability ac-
tivity showed that it could be inactivated by the ad-
dition of normal human serum; the active principle(s)
seemed to be several different apolipoproteins [82].
Although FSGS patients with recurrent disease post
transplant tend to have higher permeability activity both
before and after transplant, at present permeability activ-
ity is not a reliable predictor of post-transplant recurrence
of FSGS, nor of response to steroids in patients with pri-
mary FSGS [82]. Speculations about the so-called “Savin
factor” are interesting, and more studies are warranted.
Currently, it is not useful clinically. It is also possible that
this factor represents an epiphenomenon related to the
nephrotic state.
Reprint requests to R. Chesney, M.D., Department of Pediatrics, Le
Bonheur Children’s Medical Center, 50 North Dunlap, Room 306–307,
Memphis, Tennessee, USA 38103
E-mail: rchesney@utmem.edu
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